Target
bleomycin
7 abstracts
Abstract
Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.Org: University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), Swiss Group for Clinical Cancer Research (SAKK), Department of Internal Medicine III with Hematology,
Abstract
Albumin-bound paclitaxel, cisplatin, and bleomycin combination with tislelizumab for stage IV squamous cell carcinoma of the penis without surgical indications: A single-arm, single-center prospective phase II clinical study.Org: Cancer Hospital of HuanXing ChaoYang District Beijing,
Abstract
Seven-year overall survival analysis from ECHELON-1 study of A+AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma.Org: Antoine-Lacassagne Cancer Center, University of Tennessee Graduate School of Medicine, Takeda Pharmaceuticals International AG,
Abstract
Predictive cytokine biomarkers for immune-related adverse events associated with immune checkpoint inhibitor therapy in Hodgkin lymphoma.Org: NYU Langone Medical Center, NYU Langone Health, New York, NY, Perlmutter Cancer Center, New York University Langone Health,
Abstract
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs).Org: NHMRC Clinical Trials Centre, The University of Sydney, Peter MacCallum Cancer Centre, Melbourne, Australia, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale School of Medicine,
Abstract
Anticancer–drug-induced interstitial lung disease (DIILD): With great power comes great responsibility.Org: Syneos Health, Morrisville, NC, NC Medical Research, Gurugram, Indiana University – Purdue University Indianapolis,
Abstract
Testicular GERM cell tumors treatment outcome in a national cancer institution in Peru.Org: Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru, Universidad Nacional Federico Villareal,